Trial reportMedicine2025
Safety analysis of STA-MCA bypass combined with EDAS in the treatment of patients with moyamoya disease.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predicting cerebral hyperperfusion syndrome after STA-MCA bypass in Moyamoya disease with CT perfusion through meta-regression.Neurosurgical review · 2026Pooled it
- Topographic and morphometric anatomy of the superficial temporal artery for STA-MCA bypass in Vietnamese adults.Surgical and radiologic anatomy : SRA · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the clinical efficacy and safety of superficial temporal artery to middle cerebral artery (STA-MCA) bypass combined with encephalo-duro-arterio-synangiosis (EDAS) in the treatment of moyamoya disease. A total of 80 patients with moyamoya disease who were treated at our institution between January 2022 and January 2024 were enrolled and randomly assigned to 2 groups: a control group (n = 40) and an observation group (n = 40). The control group underwent EDAS, while the observation group received STA-MCA bypass in addition to EDAS. Surgical success rates, cerebral blood flow (CBF) efficacy markers, neurological function scores, and surgical safety were comprehensively assessed in both groups. The surgical success rate in the observation group was 95.00%, significantly higher than 75.00% in the control group (P < .05). Three days postoperatively, the observation group exhibited significantly higher CBF and cerebral blood volume compared to the control group, with reduced time to peak and mean transit time (P < .05). One month after surgery, the observation group had significantly lower modified Rankin Scale and National Institutes of Health Stroke Scale scores, and higher mini-mental state examination scores compared to the control group (P < .05). The incidence of perioperative complications was 15.00% in the observation group and 17.50% in the control group, with no significant difference between the groups (P > .05). STA-MCA bypass combined with EDAS significantly improves surgical success rates, cerebral hemodynamic parameters, and neurological function outcomes in patients with moyamoya disease without increasing the incidence of surgical complications, indicating favorable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.